Basel (Switzerland) and Shanghai (P.R.China) September 10, 2013 – Stratpharma AG and Luqa Pharmaceuticals Co., Ltd. today announce that they have signed an extension to their collaboration. The collaboration will now extend past 2020 and encompasses an expanded range of innovative medical devices in the areas of cosmetic dermatology, plastic surgery, burns, wounds & scar management as well as preferential rights to Stratpharma’s new products under development.
In February 2013 Luqa launched Stratpharma’s scar therapy gel, STRATADERM®, a novel silicone gel formulation for the treatment of scars. The product has been developed using a new silicone polymer technology, which has already become a reference treatment option across China. Under the extended collaboration agreement, Luqa Pharmaceuticals will register and commercialize Stratpharma’s innovative pipeline in China, rolling out four new products over the next three years.
Darren Kerr, Stratpharma’s C.E.O. said “The Stratpharma-Luqa collaboration has brought highly promising outcomes. The excellent results achieved since the launch of STRATADERM® in China early this year make us wish to accelerate an extended collaboration to rapidly bring Stratpharma’s new topical medical devices to the fast growing China market. We are very pleased that Luqa has elected to extend this collaboration and believe that this provides a significant endorsement of the potential of Stratpharma’s pipeline.”
Robert Braithwaite, C.E.O. of Luqa Pharmaceuticals said, “We are delighted with the progress of our collaboration with Stratpharma following the successful launch of STRATADERM® in China. Over the last years, Stratpharma and Luqa have formed a strong and close working relationship. We are excited to extend our collaboration to develop and commercialize innovative new treatments in order to further our contribution to enhance the quality of life of China’s population.”
According to the International Survey on Aesthetic/Cosmetic Procedures performed in 2011, China is the World’s fastest growing market and the third largest in number of aesthetic procedures. Global data indicates that the wound management market is forecasted to rapidly grow, especially in the advanced wound market segments, from the current USD 14 bn to USD 21 bn by 2021.
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty care segments in China. Please visit us at www.luqapharma.com
Contact: Hugo Peris (firstname.lastname@example.org)
Stratpharma specialises both in the development and in the licensing and global commercialisation of novel medical devices and pharmaceutical products. Stratpharma’s dermatology team has many years of international experience in the dermatological therapeutic franchise with a current focus on scars, wounds and chronic skin diseases. These products for scar management and abnormal scar prevention can be used alone or in combination with other more invasive therapies. The current products including Strataderm® are registered and are available in over 60 countries in Europe, North America and Asia. Please visit us at www.stratpharma.com
Contact: Darren Kerr (email@example.com)